151751-Najiba-Chargi

213 Systemic therapy: skeletal muscle mass and chemoradiotherapy 15. Zwart AT, Hoorn A, Ooijen PMA, Steen - bakkers RJHM, Bock GH, Halmos GB. CT ‐ measured skeletal muscle mass used to assess frailty in patients with head and neck cancer. J Cachexia Sarcopenia Muscle . 2019;10(5):1060-1069. doi:10.1002/ jcsm.12443 16. Sealy MJ, Dechaphunkul T, van der Schans CP, et al. Low muscle mass is associated with early termination of chemotherapy related to toxicity in patients with head and neck cancer. Clin Nutr . 2020;39(2):501-509. doi:10.1016/j.clnu.2019.02.029 17. Paleri V, Wight RG, Silver CE, et al. Comor - bidity in head and neck cancer: a criti- cal appraisal and recommendations for practice. Oral Oncol . 2010;46(10):712-719. doi:10.1016/j.oraloncology.2010.07.008 18. Swartz JE, Pothen AJ, Wegner I, et al. Feasibility of using head and neck CT im - aging to assess skeletal muscle mass in head and neck cancer patients. Oral Oncol . 2016;62:28-33. doi:10.1016/j.oraloncolo - gy.2016.09.006 19. Heymsfield SB, Wang ZM, Baumgartner RN, Ross R. Human body composition: Ad - vances in models and methods. Annu Rev Nutr . 1997;17:527-558. doi:10.1146/annurev. nutr.17.1.527 20. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sar- copenic obesity in patients with solid tu- mours of the respiratory and gastrointesti- nal tracts: a population-based study. Lancet Oncol . 2008;9(7):629-635. doi:10.1016/ S1470-2045(08)70153-0 21. Shodo R, Yamazaki K, Ueki Y, Takahashi T, Horii A. Sarcopenia predicts a poor treat - ment outcome in patients with head and neck squamous cell carcinoma receiving concurrent chemoradiotherapy. Eur Arch Oto-Rhino-Laryngology . August 2020. doi:10.1007/s00405-020-06273-4 22. Ganju RG, Morse R, Hoover A, TenNapel M, Lominska CE. The impact of sarcopenia on tolerance of radiation and outcome in patients with head and neck cancer receiving chemoradiation. Radiother Oncol . 2019;137:117-124. doi:10.1016/j. radonc.2019.04.023 23. Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-posi- tive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet . 2019;393(10166):51-60. doi:10.1016/S0140-6736(18)32752-1 24. Gillison ML, Trotti AM, Harris J, et al. Ra - diotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyn- geal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferior- ity trial. Lancet . 2019;393(10166):40-50. doi:10.1016/S0140-6736(18)32779-X 25. Gebre-Medhin M, Brun E, Engström P, et al. ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cis - platin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer. J Clin Oncol . Oc - tober 2020:JCO.20.02072. doi:10.1200/ JCO.20.02072 26. Economopoulou P, de Bree R, Kotsantis I, Psyrri A. Diagnostic tumor markers in head and neck squamous cell carcinoma (HNSCC) in the clinical setting. Front Oncol . 2019;9(AUG). doi:10.3389/fonc.2019.00827 27. Prado CM, Cushen SJ, Orsso CE, Ryan AM. Sarcopenia and cachexia in the era of obe- sity: Clinical and nutritional impact. Proc Nutr Soc . 2016;75(2):188-198. doi:10.1017/ S0029665115004279 28. Urien S, Lokiec F. Population pharmacoki - netics of total and unbound plasma cispla- tin in adult patients. Br J Clin Pharmacol . 2004;57(6):756-763. doi:10.1111/j.1365- 2125.2004.02082.x 11